Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Potenza Therapeutics

Shire Basingstoke

Shire deal with Baxalta predicted this week

Takeover talks reported to be at an advanced stage

- PMLiVE

AZ takes majority stake in cancer drug developer Acerta

Will pay $4bn for a 55% share in the Dutch biopharma company

- PMLiVE

NICE backs Xtandi but turns down Zytiga

Astellas and Medivation's pre-chemotherapy prostate cancer drug receives support

Deal Watch November 2015

Strategic business expansion or financial engineering?In November Pfizer at long last found a willing acquisition target that may provide the tax inversion it has been desperate to achieve since its...

Deal Watch October 2015

A bumper crop of deals with seven transactions of $1bn or more

- PMLiVE

AbbVie takes Company of the Year at PMEA 2015

Firm rewarded for patient-centricity, whileAstellas is highly commended

- PMLiVE

Astellas sells dermatology unit to Leo for €675m

Continuesthe company's restructuring drive

- PMLiVE

Astellas appoints Peter Sandor as head of oncology

He joins the company from Amgen

- PMLiVE

Astellas adds to regenerative medicine unit with Ocata buy

Willpay around $379m for the cell therapy specialist

- PMLiVE

Is Pfizer eyeing a merger with Allergan?

Combined company value could be $330bn

Eli Lilly HQ

Lilly and AZ forge closer immuno-oncology bond

Look to boost their presence in a market predicted to be worth $30bn in 10 years

- PMLiVE

Novartis adds to immuno-oncology pipeline once again

Aims to catch up with rivals BMS and Merck & Co.

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links